Ancilia Bio
New York, US · Founded 2019 · 22 employees on LinkedIn · 6 known investors
Ancilia is a biotech company using CRISPR to create beneficial bacterial products, such as live biotherapeutics, that carry immunity against the viruses that destroy them. It develops computational and biological platforms to identify, characterize, and counter viruses within the microbiome (the virome).
Also known as Ancilia · Ancilia Bio, Inc.
Founders & leadership
Ancilia Bio was founded in 2019 by Rodolphe Barrangou, Alex, and Davi Paez-Espino.
Board
Investors · 6
Reported raises · per SEC filings
Form D private placements$11.1M disclosed across 2 rounds · 2023–2026
▶$10.1MraisedApr 2026 · 23 investors · OtherRule 506(b)
- RODOLPHE BARRANGOUExecutive Officer, Director
- ALEXANDRA SAKATOSExecutive Officer, Director
- DALE PFOSTDirector
- VERA SCHROEDERDirector
- GURDANE BHUTANIDirector
- Offering amount
- $10.1M
- Amount sold
- $10.1M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMay 2023 · 2 investors · BiotechnologyRule 506(b)
- Dale PfostDirector
- Rodolphe BarrangouExecutive Officer, Director
- Alexandra SakatosExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Ancilia Bio is a biotechnology company working on the viral component of the microbiome (the virome) and on protecting beneficial bacteria from the viruses that infect and kill them. The company's stated premise is that while much microbiome work has focused on bacteria, at least half of the microbiome consists of viruses, and bacteriophages can limit the utility of beneficial bacteria intended for use as live biotherapeutics. Ancilia's approach is to leverage CRISPR-Cas, which it describes as a naturally evolved bacterial immune system against viruses, to "vaccinate" bacteria against predatory phages.
The company frames virome work as technically difficult because viruses are highly diverse, lack a universal marker sequence, and are hard to grow and culture in the laboratory. Its products are aimed at therapeutics, agriculture, and industrial biotechnology applications, built around new classes of live biotherapeutics and other bacterial products with engineered viral immunity.
▸Full profile — market position, technology, go-to-market, geography
Market position
Ancilia Bio positions itself around the virome and phage-resistance layer of microbiome product development, rather than around bacterial strain discovery alone, arguing that phage predation constrains the usefulness of beneficial bacteria as therapies and products.
Technology
Ancilia Bio describes two named platforms. CoVE (Computational Virome Engine) is a computational platform intended both to identify and characterize the virome and to design solutions countering the destructive properties of specific viruses. EPIC (Enhancing Phage Immunity with CRISPR) applies CRISPR's natural immune function to develop live biotherapeutics and other bacterial products carrying immunity to phages, with the aim of maintaining their efficacy across applications. The company states that these platforms rest on proprietary CRISPR tools and technologies and are intended to extend to a broader range of virome-associated applications.
Go-to-market
The company points to three application areas for its bacterial products: therapeutics, agriculture, and industrial biotechnology.
Geography
Ancilia Bio lists a single location at Biolabs @ NYU Langone, 45-18 Court Square W, Long Island City, New York 11101, United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 5
by search overlap
Companies competing with Ancilia Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
▸Research sources · 1
primary sources listed
- Ancilia Bioanciliabio.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Ancilia Bio do?
- Ancilia Bio applies CRISPR-Cas and virome science to make beneficial bacteria resistant to bacteriophages.
- Who founded Ancilia Bio?
- Ancilia Bio was founded by Rodolphe Barrangou, Alex, Davi Paez-Espino in 2019.
- Who are Ancilia Bio's investors?
- Ancilia Bio's investors include Deep Science Ventures, Metaplanet, PsyMed Ventures, Safar Partners, Snatched Ventures, Spacecadet Ventures.
- How much funding has Ancilia Bio raised?
- Ancilia Bio has disclosed $11.1M raised across 2 rounds.
- Where is Ancilia Bio headquartered?
- Ancilia Bio is headquartered in New York, US.